Robert Hugin - Celgene Chairman of the Board and Presidentident, CEO
Chairman
Mr. Robert J. Hugin is no longer Executive Chairman of the Board of the Company effective February 5, 2018. Prior thereto he was Chairman of our Board of Directors since June 2011, Chief Executive Officer since June 16, 2010, President from May 1, 2006 to July 31, 2014, Chief Operating Officer from May 1, 2006 to June 16, 2010, and Senior Vice President and Chief Financial Officer from June 1999 to May 1, 2006. Mr. Hugin has served as one of our Directors since December 2001. Previously, Mr. Hugin had been a Managing Director at J.P. Morgan Co. Inc., which he joined in 1985. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corporationration infantry officer during the intervening period. Mr. Hugin is also a Director of The Medicines Company, Danaher Corporation, Atlantic Health System, Inc., a nonprofit health care system, and Family Promise, a national nonprofit network assisting homeless families.Mr. Hugin brings to his role as a director his extensive executive and leadership experience at Celgene and his previous business experience, as well as his leadership roles on the boards of a public company and a nonprofit health care company. In particular, his experience as our Chief Executive Officer, President, Chief Operating Officer and Chief Financial Officer and his current role as our Executive Chairman enable him to provide leadership and unique insight on complex business and financial matters and guidance with respect to the strategic goals and operating framework of a high growth company such as ours. Additionally, Mr. Hugin served as Chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America from April 2013 until April 2014, is a past Chairman of the HealthCare Institute of New Jersey and is a member of the Board of Trustees of Princeton University. since 2016.
| Age | 62 |
| Tenure | 8 years |
| Phone | 908 673-9000 |
| Web | www.celgene.com |
Celgene Management Efficiency
The company has return on total asset (ROA) of 0.14 % which means that it generated a profit of $0.14 on every $100 spent on assets. This is way below average. Celgene's management efficiency ratios could be used to measure how well Celgene manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 20.1 B in liabilities with Debt to Equity (D/E) ratio of 199.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Celgene has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Celgene until it has trouble settling it off, either with new capital or with free cash flow. So, Celgene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celgene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celgene to invest in growth at high rates of return. When we think about Celgene's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Luvleen Sidhu | Bm Technologies | 37 | |
| Clarence Granger | Ultra Clean Holdings | 69 | |
| John Shoven | Cadence Design Systems | 70 | |
| David ibnAle | Ultra Clean Holdings | 46 | |
| N Murthy | Infosys Ltd ADR | 68 | |
| Dean Foate | Plexus Corp | 59 | |
| Steven Fischer | ScanSource | 72 | |
| Nandan Nilekani | Infosys Ltd ADR | 68 | |
Management Performance
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 |
Celgene Leadership Team
Elected by the shareholders, the Celgene's board of directors comprises two types of representatives: Celgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celgene. The board's role is to monitor Celgene's management team and ensure that shareholders' interests are well served. Celgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Loughlin, Independent Director | ||
| Michael Friedman, Independent Director | ||
| Michael Bonney, Director | ||
| Hans Bishop, Director | ||
| John Weiland, Director | ||
| Gerald Masoudi, Executive Vice President General Counsel and Corporate Secretary | ||
| Gilla Kaplan, Independent Director | ||
| Patricia Hall, Director | ||
| Robert Hugin, Chairman of the Board and Presidentident, CEO | ||
| Peter Kellogg, CFO, Executive Vice President | ||
| David Elkins, Executive Vice President | ||
| Perry Karsen, CEO of Celgene Cellular Therapeutics | ||
| Rupert Vessey, President - Research and Early Development | ||
| Carrie Cox, Independent Director | ||
| Terrie Curran, President Global Inflammation & Immunology Franchise | ||
| Michael Pehl, President Hematology & Oncology | ||
| Mark Alles, President, COO and Director | ||
| Alise Reicin, President - Global Clinical Development | ||
| Jonathan Biller, Executive Vice President General Counsel | ||
| Julia Haller, Director | ||
| Robert Hershberg, Chief Scientific Officer | ||
| Jacqualyn Fouse, President of Global Hematology and Oncology and Director | ||
| Ernest Mario, Independent Director | ||
| Scott Smith, President - Inflammation & Immunology | ||
| Thomas Daniel, Executive Vice President and Presidentident - Research and Early Development | ||
| Richard Barker, Independent Director | ||
| Michael Casey, Lead Independent Director |
Celgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X |
Pair Trading with Celgene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celgene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Freeport McMoran could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Freeport McMoran when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Freeport McMoran - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Freeport McMoran Copper Gold to buy it.
The correlation of Freeport McMoran is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Freeport McMoran moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Freeport McMoran Copper moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Freeport McMoran can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |